What's Going On With Regulus Therapeutics Stock Monday?
Portfolio Pulse from Dylan Berman
Regulus Therapeutics (NASDAQ:RGLS) announced topline results from its Phase 1B MAD clinical trial for RGLS8429, showing a decrease in htTKV and an increase in PC1 and PC2 proteins. Despite initially trading higher, the stock turned negative and is down 20.3% at $2.00.
June 24, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regulus Therapeutics announced positive topline results from its Phase 1B trial for RGLS8429, showing a decrease in htTKV and an increase in PC1 and PC2 proteins. Despite the positive results, the stock fell 20.3% to $2.00.
Despite the positive clinical trial results, the significant drop in stock price suggests that investors may have had higher expectations or concerns about other aspects of the trial or company. The immediate market reaction is negative.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100